Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Journal
The Lancet. Haematology
Date Issued
2023-12-05
Author(s)
Zeidan, Amer M
Ando, Kiyoshi
Rauzy, Odile
Turgut, Mehmet
Wang, Ming-Chung
Cairoli, Roberto
Kwong, Yok-Lam
Arnan, Montserrat
Meers, Stef
Pullarkat, Vinod
Santini, Valeria
Malek, Kamel
Kiertsman, Flavia
Niolat, Julie
Ramos, Pedro Marques
Menssen, Hans D
Fenaux, Pierre
Miyazaki, Yasushi
Platzbecker, Uwe
Abstract
Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the efficacy and safety of sabatolimab plus hypomethylating agent with placebo plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes.
Type
journal article